Safety of mibefradil, a new once-a-day, selective t-type calcium channel antagonist

American Journal of Cardiology

Volumn 80, Issue 4 B, 1997, Pages

  Kobrin, Isaac ^a   Charlon, Vincent ^a   Lindberg, Elisabeth ^a   Pordy, Robert ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; MIBEFRADIL; NIFEDIPINE; PLACEBO;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HUMAN; INCIDENCE; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS BRADYCARDIA; VERTIGO;

EID: 0030862952     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00569-9     Document Type: Article

References (18)

1. 2+ channels by Ro 40-5967. Circ Res. 75:1994;144-148.
2. Véniant M, Clozel J-P, Heudes D, Banken L, Ménard J. Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats. J Cardiovasc Pharmacol. 21:1993;544-551.
3. Orito K, Satoh K, Taira N. Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J Cardiovasc Pharmacol. 22:1993;293-299.
4. Schmitt R, Kleinbloesem C, Belz G, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 52:1992;314-323.
5. Braun S, van der Wall E, Emanuelsson H, Kobrin I. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol. 27:1996;317-322.
6. Bernink P, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension. 27:1996;426-432.
7. Bakx A, van der Wall E, Braun S, Emanuelsson H, Bruschke A, Kobrin I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Am Heart J. 130:1995;748-757.
8. Furberg C, Psaty B. Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side. Arch Intern Med. 155:1995;2157-2161.
9. Furberg C, Psaty B, Meyer J. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
10. Pahor M, Guralnik J, Salive M, Corti M-C, Carbonin P, Havlik R. Do calcium channel blockers increase the risk of cancer? Am J Hypertens. 9:1996;695-699.
11. Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 247:1995;620-625.
12. Lenfant C. The calcium channel blocker scare: lessons for the future. Circulation. 91:1995;2855-2856.
13. Opie L, Messerli F. Nifedipine and mortality: grave defects in the dossier. Circulation. 92:1995;1068-1073.
14. Habib G. Are calcium antagonists harmful in hypertensive patients? Chest. 108:1995;3-5.
15. Dargie H, Ford I, Fox K. Total Ischemic Burden European Trial (TIBET): effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J. 17:1996;104-112.
16. Welker H, Eggers H, Kleinbloesem C, et al. Ro 40-5967: pharmacokinetics of a new calcium antagonist. Eur J Clin Pharmacol. 36:1989;A304.
17. Clozel J-P, Osterrieder W, Kleinbloesem C, et al. Ro 40-5967: a new non-dihydropyridine calcium antagonist. Cardiovasc Drug Rev. 9:1991;4-17.
18. Rousseau M, Hayashida W, van Eyll C, et al. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol. 28:1996;972-979.